



=> d 13 que stat  
L1 STR

Buch  
989348



VAR G1=H/ME  
T= REP G2=(1-20) A  
VAR G3=16/20  
VAR G4=H/C/SI  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED  
  
GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22  
  
STEREO ATTRIBUTES: NONE  
L3 759 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 19478 ITERATIONS 759 ANSWERS  
SEARCH TIME: 00.00.11

=> e adenylyl cyclase/cn 5  
E1 1 ADENYLYL (.BETA.,.GAMMA.-METHYLENE)DIPHOSPHONATE/CN  
E2 1 ADENYLYL .BETA.,.GAMMA.-IMIDODIPHOSPHATE/CN  
E3 1 --> ADENYLYL CYCLASE/CN  
E4 1 ADENYLYL CYCLASE (AEROMONAS HYDROPHILA STRAIN 218 GENE CYAA  
ISOENZYME 1)/CN  
E5 1 ADENYLYL CYCLASE (DOG CLONE 6/27 HEART ISOFORM VI REDUCED)/C  
N

=> s e3;d ide can;e fibroproliferative vasculopathy/cn 5  
L4 1 "ADENYLYL CYCLASE"/CN

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 9012-42-4 REGISTRY  
CN Cyclase, adenylate (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Adenyl cyclase  
CN Adenylate cyclase  
CN **Adenylyl cyclase**  
CN E.C. 4.6.1.1

Searched by: Mary Hale 308-4258 CM-1 1E01

MF Unspecified  
CI MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, EMBASE,  
IFICDB, IFIPAT, IFIUDB, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

18802 REFERENCES IN FILE CA (1967 TO DATE)

42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

18810 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:18214

REFERENCE 2: 137:17453

REFERENCE 3: 137:16033

REFERENCE 4: 137:16005

REFERENCE 5: 137:4315

REFERENCE 6: 137:3303

REFERENCE 7: 137:3300

REFERENCE 8: 137:3294

REFERENCE 9: 137:3287

REFERENCE 10: 137:1968

E1 1 FIBROPELLIN III (STRONGYLOCENTROTUS PURPURATUS CLONE R1 REDU  
CED)/CN  
E2 1 FIBROPLAST/CN  
E3 0 --> FIBROPROLIFERATIVE VASCULOPATHY/CN  
E4 1 FIBROPUR P 68/CN  
E5 1 FIBROSIN (HUMAN PLACENTA REDUCED)/CN

=> fil medl,hcapl,embase,biosis,jicst;s l3 and (l4 or (adenylyl or  
adenylate)(w)cyclase or 9012-42-4 or adenine nucleotide! or fibroprolif?  
vasculopath? or fibro prolifer?(5a)vasculopath?)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
150.62	150.83

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 10:20:32 ON 09 JUL 2002

FILE 'HCAPLUS' ENTERED AT 10:20:32 ON 09 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:20:32 ON 09 JUL 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:20:32 ON 09 JUL 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'JICST-EPLUS' ENTERED AT 10:20:32 ON 09 JUL 2002

COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

Searched by: Mary Hale 308-4258 CM-1 1E01

L5 0 FILE MEDLINE  
 L6 6 FILE HCAPLUS  
 L7 0 FILE EMBASE  
 L8 0 FILE BIOSIS  
 L9 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES


L10 6 L3 AND (L4 OR (ADENYLYL OR ADENYLATE) (W) CYCLASE OR 9012-42-4  
 OR ADENINE NUCLEOTIDE! OR FIBROPROLIF? VASCULOPATH? OR FIBRO  
 PROLIFER?(5A) VASCULOPATH?)

=> d 1-6 cbib abs hitstr

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS

2002:391715 Document No. 136:386348 Preparation of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**  
 . Levy, Daniel E.; Marlowe, Charles; Kane-Maguire, Kim; Scarborough, Robert M. (Cor Therapeutics, Inc., USA). PCT Int. Appl. WO 2002040481 A2 20020523, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US43294 20011120. PRIORITY: US 2000-PV249465 20001120.

GI



AB The present invention relates to derivs. and analogs of adenine I wherein, L and Y are independently alkylidene, oxyalkylidene, aminoalkylidene, A is a direct link or A is divalent member selected from the group consisting of Ph, thienyl, furanyl, pyrrolyl, indolyl, heterocycle; Z is (CH2)nC(O)NHOH, (CH2)nCOOH; n = 0-4; which inhibit **adenylyl cyclase** activity. The present invention also relates to a method of preventing and inhibiting a patient's **fibroproliferative vasculopathy** following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amt. of a compd. according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a

patient's **fibroproliferative vasculopathy** such as chronic allograft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of **adenylyl cyclase** activity and a method for treating congestive heart failure. Thus, (1S)-1-(9-adenenyl)-3-carboxy-3-cyclopentene was prepd. as inhibitor of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy** (no data).

IT 9012-42-4, **Adenylyl cyclase**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**)

RN 9012-42-4 HCAPLUS

CN Cyclase, adenylyl (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 4323-13-1P 90973-36-7P 426226-30-4P

426226-31-5P 426226-32-6P 426226-33-7P


426226-34-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**)


RN 4323-13-1 HCAPLUS

CN 9H-Purine-9-heptanoic acid, 6-amino- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 90973-36-7 HCAPLUS

CN 9H-Purine-9-pentanoic acid, 6-amino- (9CI) (CA INDEX NAME)




RN 426226-30-4 HCAPLUS


CN 9H-Purine-9-butanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)




RN 426226-31-5 HCAPLUS  
 CN 9H-Purine-9-pentanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)




RN 426226-32-6 HCAPLUS  
 CN 9H-Purine-9-hexanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



RN 426226-33-7 HCAPLUS  
 CN 9H-Purine-9-heptanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)




RN 426226-34-8 HCAPLUS  
 CN 9H-Purine-9-hexanoic acid, 6-amino- (9CI) (CA INDEX NAME)



IT 41785-06-2P 70259-15-3P 326797-58-4P  
359865-38-6P 426226-28-0P 426226-29-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of adenine based carbocyclic nucleosides as inhibitors of  
adenylyl cyclase and for treatment of patient's  
fibroproliferative vasculopathy)


RN 41785-06-2 HCAPLUS

CN 9H-Purine-9-butanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)




RN 70259-15-3 HCAPLUS

CN 9H-Purine-9-propanoic acid, 6-amino-, methyl ester (9CI) (CA INDEX NAME)




RN 326797-58-4 HCAPLUS

CN 9H-Purine-9-pentanoic acid, 6-amino-, methyl ester (9CI) (CA INDEX NAME)




RN 359865-38-6 HCAPLUS

CN 9H-Purine-9-heptanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)




RN 426226-28-0 HCAPLUS

CN 9H-Purine-9-hexanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)



RN 426226-29-1 HCAPLUS

CN 9H-Purine-9-propanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS

1993:117336 Document No. 118:117336 Characterization of membrane-bound and solubilized high-affinity binding sites for 5'-N-ethylcarboxamido[3H]adenosine from bovine cerebral cortex. Lorenzen, Anna; Nitsch-Kirsch, Monika; Vogt, Heidrun; Schwabe, Ulrich (Pharmakol. Inst., Univ. Heidelberg, Heidelberg, D-6900, Germany). J. Neurochem., 60(2), 745-51 (English) 1993. CODEN: JONRA9. ISSN: 0022-3042.

AB A high-affinity binding site for 5'-N-ethylcarboxamido[3H]adenosine ([3H]NECA) from bovine cerebral cortex has been characterized in its membrane-bound and solubilized state after gel filtration on Sepharose CL-6B. For detection of this site in membranes, it was necessary to remove metabolites with high affinities for this site enzymically, e.g., adenosine by addn. of adenosine deaminase and inosine by addn. of nucleoside phosphorylase. The pore-forming peptide antibiotic alamethicin further enhanced binding of [3H]NECA to this site in membranes. In contrast to adenosine receptors and the adenotin-like low-affinity binding protein, this novel site was extremely sensitive against treatment with the sulfhydryl alkylating agent N-ethylmaleimide. In competition expts., this site could be differentiated from adenosine receptors by its high affinity for **adenine nucleotides** and its lack of affinity for adenosine receptor antagonists. Inosine and its deriv. S-(4-nitrobenzyl)-6-thioinosine were relatively potent ligands with Ki values in the high nano- and low micromolar range, resp. Apparently, the high-affinity NECA binding site described previously in bovine striatum is not exclusively located in the striatum, but can also be detected in membrane preps. and sol. exts. of bovine brain cortex.

IT 23918-98-1, Eritadenine


RL: BIOL (Biological study)

(NECA binding affinity for, in cerebral cortex)

RN 23918-98-1 HCAPLUS


CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, (.alpha.R,.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS  
 1981:526666 Document No. 95:126666 Eritadenine: a new tool for  
 investigation of the adenosine P site in plasma membranes of rat fat  
 cells. Soechtig, E.; Trost, T. (Abt. Allg. Pharmakol., Med. Hochsch.,  
 Hannover, Fed. Rep. Ger.). Pharmacology, 23(2), 82-90 (English) 1981.  
 CODEN: PHMGBN. ISSN: 0031-7012.

GI



AB Eritadenine (I) [23918-98-1] was investigated for its effects  
 on **adenylate cyclase** [9012-42-4] activity  
 of rat fat cell plasma membranes and on cyclic AMP [60-92-4] accumulation  
 and lipolysis in isolated rat fat cells. In rat fat cell plasma  
 membranes, a 50% inhibition of noradrenaline-stimulated **adenylate**  
**cyclase** was obtained at I and adenosine [58-61-7] concns. of 11.6  
 .mu.mol/L and 9.0 .mu.mol/L, resp. NaF-stimulated **adenylate**  
**cyclase** was inhibited at concns. of I lower than those of  
 adenosine. Eritadenine Et ester [28987-93-1] was almost  
 ineffective on **adenylate cyclase**. The inhibitory  
 effect of I was resistant to adenosine deaminase. In isolated rat fat  
 cells, I was completely ineffective to block noradrenaline-stimulated  
 cyclic AMP accumulation or lipolysis stimulated by theophylline or  
 adenosine deaminase. I may be an effector of the adenosine P site of fat  
 cell plasma membranes.

IT 23918-98-1

RL: BAC (Biological activity or effector, except adverse); BIOL  
 (Biological study)


(adenosine receptors of adipocyte cell membrane response to)

RN 23918-98-1 HCAPLUS

CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-,  
 (.alpha.R,.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 28987-93-1


RL: PRP (Properties)

(adenylate cyclase of adipocyte cell membrane in relation to)

RN 28987-93-1 HCAPLUS

CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, ethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9012-42-4

RL: BIOL (Biological study)

(of adipocyte cell membrane, eritadenine effect on, adenosine receptors in relation to)

RN 9012-42-4 HCAPLUS

CN Cyclase, adenylate (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS

1979:80803 Document No. 90:80803 Regulation of the activity of malignant cell adenyl cyclase using the synthetic adenine derivative - adenylyl-9-alanine. Gilev, A. P.; Lidaks, M. (USSR). Novosti Khimii Nukleozidov i Nukleotidov 157-8 From: Ref. Zh., Biol. Khim. 1978, Abstr. No. 20Ts1092 (Russian) 1978.

AB Title only translated.

IT 58845-56-0


RL: BIOL (Biological study)

(adenylate cyclase stimulation and cAMP phosphodiesterase inhibition by, in neoplasm)

RN 58845-56-0 HCAPLUS

CN 9H-Purine-9-propanoic acid, .alpha.,6-diamino-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9012-42-4  
 RL: PROC (Process)  
 (stimulation of, by adenylylalanine in neoplasm)  
 RN 9012-42-4 HCAPLUS  
 CN Cyclase, adenylylate (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS  
 1975:25763 Document No. 82:25763 Inhibition of protein kinase and cyclic AMP phosphodiesterase by eritadenine isoamyl ester. Possible mechanism for its biphasic effects on cyclic AMP-dependent lipolysis, steroidogenesis, and amino acid uptake. Iwai, Hajime (Sch. Med., Chiba Univ., Chiba City, Japan). J. Biochem. (Tokyo), 76(2), 419-29 (English) 1974. CODEN: JOBIAO.

GI For diagram(s), see printed CA Issue.


AB The hypolipidemic compd. eritadenine isoamyl ester (I) [33303-44-5] inhibited theophylline [58-55-9]-induced lipolysis and potentiated epinephrine [51-43-4]-induced lipolysis in rat epididymal fats cell in vitro. Epinephrine stimulated lipolysis by activating **adenylylate cyclase**: I inhibited cyclic AMP phosphodiesterase (E.C.: 3.1.4.7) [9013-53-0] of fat cells, increased the rate of cyclic AMP [60-92-4] accumulation induced by epinephrine, and potentiated cyclic AMP- induced lipolysis. I also inhibited cyclic AMP-dependent protein kinase (E.C. 2.7.1.37) [9026-43-1] of fat cells, which activates lipase: this may be related to its inhibition of theophylline-induced lipolysis. I enhanced the action of low concn. (5 .times. 10-5-5 .times. 10-4 M) and suppressed the action of high concn. (10-3M) of dibutyryl cyclic AMP [362-74-3] on lipolysis, amino acid uptake by liver, and steroidogenesis by the adrenal glands.

IT 33303-44-5  
 RL: BIOL (Biological study)  
 (lipolysis response to, cyclic AMP phosphodiesterase and protein kinase in relation to)

RN 33303-44-5 HCAPLUS

CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, 3-methylbutyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2002 ACS

1974:67752 Document No. 80:67752 Potent magnesium-dependent inhibition of **adenylate cyclase** activity from guinea pig lung by adenosine and other 9-substituted adenines. Weinryb, Ira; Michel, Inge M. (Dep. Biochem, Pharmacol, Squibb Inst. Med. Res., Princeton, N. J., USA). Biochim. Biophys. Acta, 334(1), 218-25 (English) 1974. CODEN: BBACAQ.

AB The inhibition of **adenylate cyclase** (EC 4.6.1.1) from guinea pig lung by adenosine and a no. of 9-substituted adenines was Mg<sup>2+</sup>-dependent, the compds. being up to 13 times more potent at satg. or near satg. Mg<sup>2+</sup> concns. (11.8mM) than at limiting (1.8mM) concns. Inhibition by adenine and 6-mercaptopurine did not show a Mg<sup>2+</sup> dependence. The most potent inhibitors of cyclase activity at 11.8mM Mg<sup>2+</sup> of the 9-substituted adenines tested were: 9-(5-methyl-2-tetrahydrofuryl)adenine (I<sub>50</sub> = 8.mu.M), 9-(tetrahydro-2-furyl)adenine (I<sub>50</sub> = 10.mu.M), 9-cyclopentyladenine (I<sub>50</sub> = 20.mu.M), and 9-furfuryladenine (I<sub>50</sub> = 26.mu.M). The inhibition of lung cyclase activity by 9-(tetrahydro-2-furyl)adenine was deduced to be hyperbolic noncompetitive at 1.8mM (K<sub>i</sub> = 1.2 .times. 10<sup>-4</sup>M) and 11.8mM (K<sub>i</sub> = 2.5 .times. 10<sup>-6</sup>M) Mg<sup>2+</sup> from anal. of double-reciprocal plots; these plots showed a concave downward nonlinearity in the presence of inhibitor at both Mg<sup>2+</sup> concns. This nonlinearity was eliminated under conditions where Mg<sup>2+</sup> levels were never in excess of those of ATP. Hill plots of the inhibition by 9-(tetrahydro-2-furyl)adenine (and by adenosine) suggested that neg. cooperativity is involved in binding to the enzyme. The possibility that the Mg<sup>2+</sup>-dependence of inhibitory potency of adenosine and its analogs functions as a cellular control mechanism is discussed.


IT 23919-15-5

RL: BIOL (Biological study)

(**adenylate cyclase** inhibition by, magnesium effect on)

RN 23919-15-5 HCAPLUS

CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy- (9CI) (CA INDEX NAME)



IT 9012-42-4

RL: BIOL (Biological study)

(inhibition of lung, by adenine derivs., magnesium effect on)

RN 9012-42-4 HCAPLUS

CN Cyclase, adenylate (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> fil caol;s 13

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

92.10

242.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.72

-3.72

Searched by: Mary Hale 308-4258 CM-1 1E01

FILE 'CAOLD' ENTERED AT 10:21:19 ON 09 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L11 4 L3

=> d 1-4

L11 ANSWER 1 OF 4 CAOLD COPYRIGHT 2002 ACS

AN CA65:7178h CAOLD

TI Michael-type reactions with adenine

AU Lira, Emil P.; Huffman, C. W.

IT 711-64-8 4244-47-7 7051-59-4 7051-64-1 7051-65-2  
7083-40-1 92503-72-5 94626-13-8

L11 ANSWER 2 OF 4 CAOLD COPYRIGHT 2002 ACS

AN CA63:18872g CAOLD

TI nonclassical antimetabolites - (XXII) simulation of 5'-phosphoribosyl binding (5) inhibition of succino-adenylate kinosynthetase by 6-mercapto-9-purinyal alkanolic acid derivs. of 4- and 5-aminosalicylic acid  
AU Baker, Bernard R.; Tanna, P. M.

IT 2545-91-7 2646-81-3 3275-78-3 4323-00-6 4323-01-7 4323-02-8  
4323-03-9 4323-04-0 4323-05-1 4323-06-2 4323-07-3 4323-08-4  
4323-09-5 4323-10-8 4323-11-9 4323-12-0 4323-13-1  
4323-17-5 4323-18-6 4323-19-7 4369-82-8 4369-84-0 4418-13-7  
5187-88-2

L11 ANSWER 3 OF 4 CAOLD COPYRIGHT 2002 ACS

AN CA63:16350g CAOLD

TI 2-(.alpha.-hydroxybenzyl)benzimidazole analogs - (I) synthesis of 8-(.alpha.-hydroxybenzyl)purines, the diaza analogs of 2-(.alpha.-hydroxybenzyl)benzimidazole

AU Haggerty, William J., Jr.; Springer, R. H.; Cheng, C. C.

IT 2260-33-5 2836-31-9 4244-40-0 4244-41-1 4244-43-3 4244-44-4  
4244-45-5 4244-47-7 4244-49-9 4244-51-3 4244-52-4  
4244-53-5 4244-54-6 4244-55-7 4244-56-8 4244-58-0 4289-23-0  
4289-25-2 4301-59-1 4367-64-0 4460-07-5 4460-08-6 4460-09-7  
4460-10-0 4538-20-9 34397-00-7 97317-88-9 98882-63-4 99785-41-8

L11 ANSWER 4 OF 4 CAOLD COPYRIGHT 2002 ACS

AN CA60:4402g CAOLD

TI nonclassical antimetabolites - (XIII) simulation of the 5'-phosphoribosyl moiety of 5'-adenylic acid at the enzyme level by .omega.-carboxyalkyl and aralkyl groups attached to adenine

AU Baker, Bernard R.; Sachdev, H. S.

IT 3342-88-9 17756-30-8 28492-53-7 34397-01-8 34397-05-2 82222-85-3

Searched by: Mary Hale 308-4258 CM-1 1E01